Next week you could nearly drown in data, considering the flood of earnings reports that are coming. But don’t panic, our traders will keep you afloat.
Stocks closed higher despite some selling in the final half hour of trading, giving the market its sixth straight weekly gain and its longest weekly winning streak since 2007.
With stocks rallying for 5 weeks in a row now, dividend yields are falling back to Earth. The average dividend yield of the Dow 30 has fallen over 25% since the rally began in early March. See how the 30 companies in the Dow compare.
Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome. The announcement came out Wednesday evening that Merck is hooking up with CRME in yet another partnership deal between big pharma and baby biotech.
Stocks fell Monday amid doubts over the health of the banking industry and the apparent collapse of a major deal in the technology sector.
Breakthrough diabetes treatments may be on the horizon. What companies stand to win?
Shares of Amylin Pharmaceuticals are rallying on a press release from AMLN and its partners Eli Lilly and Alkermes that their once-a-week version of the injectable diabetes drug Byetta (buy-ate-uh) lowered blood sugar levels more than the pills Januvia from Merck and Actos from Takeda.
Stocks capped a relatively good week with a thud Friday as investors locked in profits.
Stocks ended a strong two-week run with a thud Friday as financial stocks took a beating and weakness seeped into other sectors.
The Dow slid on Friday after the Federal Reserve's plan to rekindle consumer and small business lending fell short of expectations...
Stocks were mixed Friday after a strong two-week run as financial stocks continued to struggle as some investors locked in profits. Still, Wall Street could close with its first string of consecutive positive weeks in nearly a year.
The Dow fell on Thursday largely due to concerns that the Federal Reserve's latest efforts to battle the recession are too costly and untested...
US Markets recorded their best week since November, riding four consecutive days of gains, making traders question whether we have found the bottom or if this is merely a bear bounce.
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.
Anyone out there who sees hope in the stock market must be on drugs. And I am: Lipitor and Novasc from Pfizer, Vasotec from Merck, and four other pills, all of which I gobble every day to stop myself from blowing a gasket. So let me say, with some personal pill-popping experience, that this may be a great time to buy drug stocks.
Even better: Events that could push the Dow up another 1,000 points.
Stocks bounced back after a rocky start Thursday as oil prices rebounded and investors were cheered by a better-than-expected retail-sales.
They may have the same name, but America's oldest teenager Dick Clark and Merck's Chairman and CEO Dick Clark appear to have little else in common. One loves the camera, the other not so much.
With cash scarce, credit tight and big drug companies intent on branching into biotechnology themselves, struggling bio-tech start-ups may no longer get second and third chances to succeed from thier investors, the New York Times reports.
The Dow fell modestly in choppy trade after comments from billionaire investor Warren Buffett dragged down sentiment on Monday.